Clinical trial · Other
A Study of GSBR-1290 in Healthy Participants and Participants With Type 2 Diabetes
StructureTx-GSBR1290-Ph1
Trial identity
- Registry
- Other
- Registry ID
- StructureTx-GSBR1290-Ph1
- Phase
- Phase 1
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Completed
- Result status
- partial
Sponsors & collaborators
- Sponsor
- Structure Therapeutics
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| GSBR-1290 | GSBR-1290 oral once daily | — |
| Placebo | placebo oral once daily | — |
Population & enrollment
- Population summary
- Healthy volunteers and adults with type 2 diabetes.
- Eligibility summary
- BMI 18-40 kg/m²; stable health or T2D on metformin.
- Planned enrollment
- 120
- Actual enrollment
- 120
Endpoints
- Primary endpoints
Safety and tolerability
Pharmacokinetics
- Secondary endpoints
Pharmacodynamics
Body weight change
Dates
- Start date
- Mar 10, 2022
- Primary completion
- Jun 1, 2023
- Completion date
- Sep 1, 2023
- Last synced
- Aug 15, 2024
Locations
- United States
Plain-language interpretation
A Study of GSBR-1290 in Healthy Participants and Participants With Type 2 Diabetes is a Phase 1 Interventional sponsored by Structure Therapeutics. It is evaluating GSBR-1290 in Healthy volunteers and adults with type 2 diabetes.. The primary endpoints are Safety and tolerability; Pharmacokinetics.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against Other.